1
TÍTULO: The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma  Full Text
AUTORES: Manfred P Lutz; John R Zalcberg; Michel Ducreux; Antoine Adenis; William Allum; Daniela Aust; Fatima Carneiro ; Heike I Grabsch; Pierre Laurent Puig; Florian Lordick; Markus Moehler; Stefan Monig; Radka Obermannova; Guillaume Piessen; Angela Riddell; Christoph Roecken; Franco Roviello; Paul Magnus Schneider; Stefan Seewald; Elizabeth Smyth; Eric van Cutsem; Marcel Verheij; Anna Dorothea Wagner; Florian Otto; ...Mais
PUBLICAÇÃO: 2019, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 112
INDEXADO EM: Scopus WOS CrossRef: 2
2
TÍTULO: Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018  Full Text
AUTORES: Deepak B Vangala; Estelle Cauchin; Judith Balmana; Lucian Wyrwicz; Eric van Cutsem; Ulrich Guller; Antoni Castells; Fatima Carneiro ; Pascal Hammel; Michel Ducreux; Jean Luc van Laethem; Tamara Matysiak Budnik; Wolff Schmiegel;
PUBLICAÇÃO: 2018, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 104
INDEXADO EM: Scopus WOS CrossRef: 2
3
TÍTULO: Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona  Full Text
AUTORES: Alexander Baraniskin; Jean Luc Van Laethem; Lucjan Wyrwicz; Ulrich Guller; Harpreet S Wasan; Tamara Matysiak Budnik; Thomas Gruenberger; Michel Ducreux; Fatima Carneiro ; Eric Van Cutsem; Thomas Seufferlein; Wolff Schmiegel;
PUBLICAÇÃO: 2017, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 86
INDEXADO EM: Scopus WOS CrossRef
4
TÍTULO: Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer  Full Text
AUTORES: Manfred P Lutz; John R Zalcberg; Rob Glynne Jones; Theo Ruers; Michel Ducreux; Dirk Arnold; Daniela Aust; Gina Brown; Krzysztof Bujko; Christopher Cunningham; Serge Evrard; Gunnar Folprecht; Jean Pierre Gerard; Angelita Habr Gama; Karin Haustermans; Torbjorn Holm; Koert F Kuhlmann; Florian Lordick; Gilles Mentha; Markus Moehler; Iris D Nagtegaal; Alessio Pigazzi; Salvatore Puciarelli; Arnaud Roth; Harm Rutten; Hans Joachim Schmoll; Halfdan Sorbye; Eric Van Cutsem; Juergen Weitz; Florian Otto; ...Mais
PUBLICAÇÃO: 2016, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 63
INDEXADO EM: Scopus WOS CrossRef
5
TÍTULO: Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
AUTORES: Francis Levi; Michel Ducreux; Denis Michel Smith; Mohamed Hebbar; Celine Lepere; Focan, CNJ; Rosine Guimbaud; Pasquale F Innominato; Carlos Carvalho; Salvatore Tumolo; Stephanie Truant; Denis Castaing; Abdoulaye Karaboue; Valerie Boige; Mohamed Bouchahda; Philippe Rougier; Rene Adam;
PUBLICAÇÃO: 2014, FONTE: 50th Annual Meeting of the American-Society-of-Clinical-Oncology in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 32, NÚMERO: 15
INDEXADO EM: WOS
6
TÍTULO: Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
AUTORES: Francis Levi; Abdoulaye Karaboue; Raphael Saffroy; Elodie Peyric; Michel Ducreux; Denis Michel Smith; Mohamed Hebbar; Pasquale F Innominato; Simon Pernot; Carlos Carvalho; Rosine Guimbaud; Focan, CNJ; Mohamed Bouchahda; Rene Adam; Marie Christine Etienne Grimaldi; Gerard A Milano; Antoinette Lemoine;
PUBLICAÇÃO: 2014, FONTE: 50th Annual Meeting of the American-Society-of-Clinical-Oncology in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 32, NÚMERO: 15
INDEXADO EM: WOS
7
TÍTULO: Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228).
AUTORES: Michel Ducreux; Pasquale F Innominato; Mohamed Hebbar; Denis Michel Smith; Celine Lepere; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Sameh Awad; Stephanie Truant; Denis Castaing; Abdoulaye Karaboue; Thierry De Baere; Francis Kunstlinger; Mohamed Bouchahda; Valerie Boige; Philippe Rougier; Rene Adam; Francis Levi;
PUBLICAÇÃO: 2013, FONTE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, NÚMERO: 15
INDEXADO EM: WOS
8
TÍTULO: Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer  Full Text
AUTORES: Manfred P Lutz; John R Zalcberg; Michel Ducreux; Jaffer A Ajani; William Allum; Daniela Aust; Yung Jue Bang; Stefano Cascinu; Arnulf Hoelscher; Janusz Jankowski; Edwin P M Jansen; Ralf Kisslich; Florian Lordick; Christophe Mariette; Markus Moehler; Tsuneo Oyama; Arnaud Roth; Josef Rueschoff; Thomas Ruhstaller; Raquel Seruca ; Michael Stahl; Florian Sterzing; Eric van Cutsem; Ate van der Gaast; Jan van Lanschot; Marc Ychou; Florian Otto; ...Mais
PUBLICAÇÃO: 2012, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 48, NÚMERO: 16
INDEXADO EM: Scopus WOS CrossRef
9
TÍTULO: First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)
AUTORES: Francis Levi; Michel Ducreux; Mohamed Hebbar; Philippe Rougier; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Pasquale F Innominato; Yves Ajavon; Denis Castaing; Thierry De Baere; Abdoulaye Karaboue; Celine Lepere; Valerie Boige; Laetitia Proux; Rene Adam; Mohamed Bouchahda;
PUBLICAÇÃO: 2012, FONTE: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 30, NÚMERO: 15
INDEXADO EM: WOS